Last reviewed 2026-05-14 · How we verify

V920 Consistency Lot A

V920 is a vaccine candidate designed to stimulate immune responses against varicella-zoster virus (VZV) to prevent herpes zoster and post-herpetic neuralgia.

V920 is a vaccine candidate designed to stimulate immune responses against varicella-zoster virus (VZV) to prevent herpes zoster and post-herpetic neuralgia. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of post-herpetic neuralgia in adults aged 50 years and older.

At a glance

Mechanism of action

V920 is a recombinant zoster vaccine that uses non-live viral antigens to elicit cell-mediated and humoral immune responses against VZV. By boosting immunity to the virus that causes shingles, the vaccine aims to reduce the incidence and severity of herpes zoster and its complications, particularly in older adults and immunocompromised populations.

Approved indications

• Prevention of herpes zoster (shingles) in adults aged 50 years and older
• Prevention of post-herpetic neuralgia in adults aged 50 years and older

Common side effects

• Injection site erythema
• Injection site pain
• Myalgia
• Fatigue

Key clinical trials

• Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• V920 Consistency Lot A CI brief — competitive landscape report
• V920 Consistency Lot A updates RSS · CI watch RSS
• Merck Sharp & Dohme LLC portfolio CI